Adalimumab-Aqvh

Introduction Overview

Generic Name

adalimumab-aqvh

Brand Name

Yusimry

Dosage Form

subcutaneous injection

Drug Class

TNF alfa inhibitors

Pharmacokinetics

Absorption: Adalimumab-aqvh is administered subcutaneously and exhibits relatively slow and incomplete absorption compared to intravenous routes. Peak serum concentrations are typically reached within 2 to 7 days post-injection. The bioavailability of adalimumab biosimilars such as Yusimry is approximately 64%, consistent with other adalimumab products. Factors influencing absorption include injection site blood flow, patient body mass, and concomitant immunogenicity that may accelerate clearance. Variability in absorption kinetics can influence therapeutic responses and necessitate individualized dosing.

Distribution: After absorption, adalimumab distributes predominantly within the vascular and interstitial compartments. Volume of distribution is approximately 5 to 6 liters, indicative of limited extravascular tissue penetration typical of large monoclonal antibodies. It binds to soluble and membrane-bound tumor necrosis factor alpha (TNF-α), with high affinity, which influences its apparent distribution. The drug does not readily cross the blood-brain barrier. Protein binding is specific to TNF-α molecules rather than nonspecific plasma protein interactions.

Metabolism: Being a monoclonal antibody, adalimumab is degraded via proteolytic catabolism into small peptides and amino acids through standard immunoglobulin degradation pathways predominantly in the reticuloendothelial system. It is neither metabolized by cytochrome P450 enzymes nor undergoes hepatic metabolism typical of small molecules. Immunogenicity may alter pharmacokinetics by enhancing clearance via anti-drug antibodies.

Elimination: Elimination of adalimumab occurs through a nonlinear, saturable process involving target-mediated drug disposition and nonspecific proteolytic degradation. The average elimination half-life of adalimumab biosimilars is approximately 2 weeks (10 to 20 days), supporting dosing intervals every 1 to 2 weeks. Renal excretion is negligible due to the large molecular size. Clearance rates can be increased in patients generating anti-adalimumab antibodies, potentially reducing efficacy. No dose adjustments are typically required in hepatic or renal impairment due to catabolic clearance mechanisms.

Dosage Forms

Available Dosage Forms: Yusimry is available as a subcutaneous injection delivered through two main types of prefilled devices:
- Yusimry Pen: single-dose prefilled pen containing 40 mg/0.8 mL
- Yusimry Prefilled Syringe: single-dose prefilled glass syringe containing 40 mg/0.8 mL

Dosages for Adults and Adolescents: The dosing regimen of Yusimry varies depending on the treated condition, age, and disease severity. Typical adult dosages for rheumatoid arthritis and other autoimmune diseases often start with 40 mg every other week, with potential escalation to 40 mg weekly based on clinical response and concomitant therapy. For juvenile idiopathic arthritis, dosing is weight-based, with typical initiation from 20 mg to 40 mg dosing every other week for children aged 2 years and older. Dose adjustments are made according to individual tolerance and disease activity.

Specific Patient Populations: In pediatric patients (≥2 years), dosing is adjusted by body weight; younger children may receive lower doses to achieve serum therapeutic levels. No specific alterations are generally recommended for elderly patients though caution is advised, given increased infection risk. Renal and hepatic impairments do not necessitate dose changes due to monoclonal antibody elimination pathways. Caution is advised in patients with active infections or latent tuberculosis, and vaccination status must be assessed prior to initiation.

Mechanism Of Action

Yusimry (adalimumab-aqvh) is a recombinant human monoclonal antibody that specifically binds to tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine pivotal in the pathogenesis of various autoimmune and inflammatory disorders. TNF-α exists in both soluble and transmembrane forms; Yusimry neutralizes the biological activity of soluble TNF-α by preventing its interaction with TNF receptors on cell surfaces.

At the molecular level, by binding both soluble and membrane-bound TNF-α, Yusimry inhibits downstream signaling pathways that lead to the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and other transcription factors responsible for the propagation of inflammatory mediators. This blockade reduces leukocyte recruitment, cytokine production, and expression of adhesion molecules, ameliorating the inflammatory response.

The binding to transmembrane TNF-α also mediates apoptosis of TNF-α–expressing cells and may modulate immune cell function, contributing to its immunosuppressive effects. Compared to other TNF inhibitors, Yusimry shares the same primary mode of action as its reference product Humira but is produced by a different manufacturer as a biosimilar, with demonstrated equivalent efficacy and safety profiles.

Clinically, this mechanism results in decreased joint inflammation, skin lesions, and gastrointestinal inflammation seen in diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. The neutralization of TNF-α helps restore immune homeostasis and tissue integrity, improving symptoms and halting disease progression as substantiated by numerous clinical trials of adalimumab products.

Pharmacological Actions

Neutralization of tumor necrosis factor alpha (TNF-α) to diminish inflammatory processes
Inhibition of inflammatory cytokine production and leukocyte activation
Blocking TNF-α interaction with its receptors on cell surfaces to prevent downstream signaling
Induction of apoptosis in TNF-α-expressing immune cells
Reducing synovial inflammation and joint damage in rheumatoid arthritis
Decreasing skin cell proliferation and inflammation in plaque psoriasis
Modulation of immune response in inflammatory bowel diseases such as Crohn's disease and ulcerative colitis
Suppression of disease activity in ankylosing spondylitis and psoriatic arthritis
Alleviation of ocular inflammation in uveitis
Improvement of symptoms in juvenile idiopathic arthritis
Immunomodulatory action leading to reduced tissue destruction in autoimmune diseases
Reduction of systemic inflammation markers across multiple autoimmune conditions
Partial restoration of immune tolerance by modulating inflammatory pathways
Comparable efficacy and safety profile to reference biologic Humira
Does not possess immunosuppressive properties outside TNF-α inhibition

Therapeutic Or Clinical Uses

Treatment of active moderate to severe rheumatoid arthritis in adults, alone or in combination with methotrexate or other DMARDs
Management of moderate to severe polyarticular juvenile idiopathic arthritis in children aged 2 years and older
Therapy for psoriatic arthritis in adults, as monotherapy or with non-biologic DMARDs
Treatment of ankylosing spondylitis in adult patients
Management of moderate to severe hidradenitis suppurativa in adults
Induction and maintenance treatment of moderate to severe Crohn's disease in patients 6 years and older
Treatment of moderate to severe ulcerative colitis in adults
Therapy for chronic severe plaque psoriasis requiring systemic or phototherapy
Management of non-infectious intermediate, posterior, and panuveitis in adult patients
Reduction of inflammation and prevention of tissue damage in autoimmune diseases mediated by TNF-α
Improvement of physical function and pain symptoms associated with autoimmune inflammatory disorders
Disease-modifying treatment aimed at slowing disease progression
An option for patients intolerant or not responsive to other biologic therapies in approved indications
Use in long-term disease management protocols with monitoring for safety and effectiveness
FDA-approved indications supported by clinical trial evidence of efficacy and safety

Side Or Adverse Effects

Injection site reactions including redness, swelling, itching, or bruising
Increased susceptibility to infections, including serious and potentially fatal infections like tuberculosis, bacterial sepsis, and invasive fungal infections
Headache
Upper respiratory tract infections such as sinusitis and sore throat
Rash and other hypersensitivity reactions including urticaria
Development or worsening of psoriasis, including paradoxical psoriasiform reactions
Lymphoma and other malignancies including rare hepatosplenic T-cell lymphoma, particularly in younger patients
Signs of lupus-like syndrome including joint pain, rash, and chest pain
Neurological symptoms such as numbness, tingling, dizziness, or vision changes potentially indicating demyelinating disorders
Hepatic injury manifesting as jaundice, abdominal pain, dark urine, or elevated liver enzymes
Gastrointestinal disturbances including diarrhea
Allergic reactions ranging from mild hypersensitivity to severe anaphylaxis
Potential reactivation of hepatitis B virus in carriers
Fatigue and malaise
Risk of hematologic abnormalities like pancytopenia or aplastic anemia

Precautions

Prior to initiation, screen for latent tuberculosis infection and treat as necessary
Monitor closely for signs and symptoms of infection during treatment; withhold treatment if infection occurs
Avoid live vaccines during therapy and until immune function is restored
Evaluate patients for chronic or recurrent infections before therapy
Use cautiously in patients with a history of demyelinating disease, heart failure, or malignancy
Ensure pediatric patients are up to date with all recommended immunizations before starting therapy
Use caution in patients with a history of hepatitis B; monitor hepatic function regularly
Consider risk-benefit in patients with pre-existing malignancies
Avoid concomitant use with other biologic immunosuppressants due to increased risk of infection
Inspect injection site prior to administration to avoid injecting into inflamed or damaged skin
Educate patients on appropriate injection technique and needle disposal
In pregnancy, assess potential risks and benefits; inform neonatologists if exposure occurred to manage vaccination plans
In breastfeeding, balance maternal need against potential infant exposure risks
Monitor for allergic or infusion-related reactions during and after administration
Advise patients to report any signs of infection, unusual bleeding, or systemic symptoms promptly

Warnings

Yusimry suppresses the immune system and increases risk of serious infections, including tuberculosis, bacterial sepsis, invasive fungal infections, and opportunistic infections
Patients should be tested for latent tuberculosis prior to therapy; monitoring during treatment is essential to detect new or reactivated TB
Potential increased risk of malignancies including lymphoma and other cancers, especially in pediatric and young adult Crohn’s disease or ulcerative colitis patients
Do not initiate treatment in patients with active infections; delay therapy until infections are controlled
Rare cases of serious hypersensitivity and anaphylaxis have been reported following administration
Avoid use concomitantly with other TNF-blockers or biologic immunosuppressants due to additive toxicity
Live vaccines should not be given during treatment due to impaired immune response
Potential risk of demyelinating diseases including multiple sclerosis-like syndromes
Patients with heart failure should be closely monitored; exacerbation of CHF has been observed
May cause lupus-like syndrome with symptoms such as joint pain and rash
Use in pregnancy and breastfeeding should be cautious; benefits must outweigh risks
Injection site reactions can occur and may require symptomatic management
Monitor liver function as hepatotoxicity has been reported
Older adults may be more susceptible to infections or malignancies while on therapy
Risk of reactivation of hepatitis B in carriers necessitates screening before treatment

Contraindication

Known hypersensitivity or allergy to adalimumab, any component of Yusimry, or latex (due to needle cover containing latex)
Active severe infections including sepsis, tuberculosis, fungal, bacterial, viral, or other opportunistic infections
Patients receiving concurrent treatment with other TNF inhibitors or biologic immunosuppressive agents
Individuals with moderate to severe heart failure (NYHA class III/IV)
Patients with a history of malignancies where risk exceeds potential benefit
Use in patients with active hepatitis B infection without appropriate antiviral treatment
Patients with demyelinating neurologic disorders such as multiple sclerosis
Known intolerance or history of severe allergic reaction to monoclonal antibodies
Contraindicated if injection site is inflamed, infected, or damaged
Not recommended for use in children younger than approved age indications without specific guidance
Use contraindicated during administration of live vaccines or if recent live vaccination has been administered
Patients with hematologic abnormalities like pancytopenia unless benefits outweigh risks
Known history of hypersensitivity reactions to previous biologic therapy
Contraindicated in individuals with known latex allergy due to autoinjector needle cover
Patients with congestive heart failure who have experienced worsening symptoms during TNF-alpha blockade

Drug Interactions

Concurrent use with other biologic TNF inhibitors such as etanercept, infliximab, certolizumab, golimumab increases risk of infections and is generally contraindicated
Combination therapy with anakinra or abatacept may increase immunosuppression and infection risk
Use with azathioprine or 6-mercaptopurine can increase immunosuppressive effects but requires caution and monitoring
Live vaccines are contraindicated during treatment due to potential lack of adequate immune response and risk of vaccine-related infection
Concomitant use with rituximab may potentiate immunosuppressive effects
Certain antibiotics can be co-administered; however, clinical discretion is required especially if infection risk is present
Interactions with corticosteroids primarily involve cumulative immunosuppressive effects increasing infection risk
Pharmacokinetic interactions are minimal as adalimumab is not metabolized via cytochrome P450 enzymes
Herbal immunomodulators should be used cautiously due to unpredictable effects on immune system
Avoid concomitant administration with methotrexate without close monitoring, especially in combination therapy for rheumatoid arthritis
Concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) generally safe but monitor for additive toxicity
No significant interactions expected with most oral contraceptives
Caution with drugs that affect immune function such as cyclophosphamide, azathioprine, or mycophenolate mofetil
Potential interference with diagnostic tests for tuberculosis and other infections due to immunosuppressive effects
Drug interaction potential with vaccines necessitates appropriate immunization timing and scheduling

Preparations Of The Drug

Yusimry Pen: single-dose prefilled pen containing 40 mg/0.8 mL solution for subcutaneous injection
Yusimry Prefilled Syringe: single-dose prefilled glass syringe containing 40 mg/0.8 mL solution for subcutaneous injection
Formulated with inactive ingredients including glycine, L-histidine and its hydrochloride monohydrate, polysorbate 80, sodium chloride, and water for injection
pH adjusted with sodium hydroxide as needed
Packaged in light-protective cartons to maintain stability
Storage recommendation: refrigerate at 2ºC to 8ºC (36ºF to 46ºF), do not freeze
May be stored at room temperature (up to 25ºC/77ºF) for up to 14 days if necessary; discard if not used within this period
Single-dose use only; discard any unused portion
Needle cover in the autoinjector contains natural rubber latex; contraindicated in patients allergic to latex
Each preparation is sterile and preservative-free
Must be inspected visually for particulate matter and discoloration before administration; do not use if cloudy or altered
Administration devices are designed for convenience and self-injection after appropriate training
Disposal of needles and syringes must follow local regulations for sharps waste
No vial presentations are available for Yusimry, differing from some other adalimumab products
Manufactured by Coherus BioSciences, Inc., Redwood City, California, USA